Group 1 - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for the consistency evaluation of its generic drug, Ampicillin Sodium Injection [1][2] - The approved specifications for Ampicillin Sodium Injection are 1.0g and 0.5g, and it is classified as a chemical drug [1][3] - The drug is indicated for various infections caused by sensitive bacteria, including respiratory, gastrointestinal, urinary tract, soft tissue infections, endocarditis, meningitis, and sepsis [3][4] Group 2 - The sales revenue for Ampicillin Sodium Injection in 2024 is projected to be RMB 1.1507 million, while the drug's sales in the domestic market for 2023 were RMB 69.201 million [4] - The company has invested approximately RMB 1.8284 million in the research and development of the consistency evaluation project for Ampicillin Sodium Injection [4] Group 3 - The company also announced that its subsidiary, Baiyunshan Pharmaceutical Factory, received approval for the supplementary application of Hepatitis B Detoxification Capsules and Purple Flower Azalea Capsules [6][8] - The Hepatitis B Detoxification Capsules are indicated for hepatitis B with symptoms of liver heat and have a specification of 0.25g per capsule [10] - The sales revenue for Hepatitis B Detoxification Capsules in 2023 was RMB 390,000, and the company has invested about RMB 100,000 in the research and development of this product [10]